Literature DB >> 17940981

Filovirus research: knowledge expands to meet a growing threat.

Mike Bray1, Frederick A Murphy.   

Abstract

Mesh：

Year:  2007        PMID： 17940981     DOI： 10.1086/520552

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  18 in total

1.  Ebolavirus VP35 is a multifunctional virulence factor.

Authors:  Daisy W Leung; Kathleen C Prins; Christopher F Basler; Gaya K Amarasinghe
Journal:  Virulence       Date:  2010-11-01       Impact factor: 5.882

2.  Differential Regulation of Interferon Responses by Ebola and Marburg Virus VP35 Proteins.

Authors:  Megan R Edwards; Gai Liu; Chad E Mire; Suhas Sureshchandra; Priya Luthra; Benjamin Yen; Reed S Shabman; Daisy W Leung; Ilhem Messaoudi; Thomas W Geisbert; Gaya K Amarasinghe; Christopher F Basler
Journal:  Cell Rep       Date:  2016-02-11       Impact factor: 9.423

Review 3.  Emerging targets and novel approaches to Ebola virus prophylaxis and treatment.

Authors:  Jin Huk Choi; Maria A Croyle
Journal:  BioDrugs       Date:  2013-12       Impact factor: 5.807

4.  Ebola virus VP24 targets a unique NLS binding site on karyopherin alpha 5 to selectively compete with nuclear import of phosphorylated STAT1.

Authors:  Wei Xu; Megan R Edwards; Dominika M Borek; Alicia R Feagins; Anuradha Mittal; Joshua B Alinger; Kayla N Berry; Benjamin Yen; Jennifer Hamilton; Tom J Brett; Rohit V Pappu; Daisy W Leung; Christopher F Basler; Gaya K Amarasinghe
Journal:  Cell Host Microbe       Date:  2014-08-13       Impact factor: 21.023

5.  Filovirus emergence and vaccine development: a perspective for health care practitioners in travel medicine.

Authors:  Uzma N Sarwar; Sandra Sitar; Julie E Ledgerwood
Journal:  Travel Med Infect Dis       Date:  2010-06-26       Impact factor: 6.211

6.  Structural and functional characterization of Reston Ebola virus VP35 interferon inhibitory domain.

Authors:  Daisy W Leung; Reed S Shabman; Mina Farahbakhsh; Kathleen C Prins; Dominika M Borek; Tianjiao Wang; Elke Mühlberger; Christopher F Basler; Gaya K Amarasinghe
Journal:  J Mol Biol       Date:  2010-04-24       Impact factor: 5.469

7.  Ebola virus-like particles stimulate type I interferons and proinflammatory cytokine expression through the toll-like receptor and interferon signaling pathways.

Authors:  Natarajan Ayithan; Steven B Bradfute; Scott M Anthony; Kelly S Stuthman; John M Dye; Sina Bavari; Mike Bray; Keiko Ozato
Journal:  J Interferon Cytokine Res       Date:  2013-10-08       Impact factor: 2.607

8.  Development of RNA aptamers targeting Ebola virus VP35.

Authors:  Jennifer M Binning; Tianjiao Wang; Priya Luthra; Reed S Shabman; Dominika M Borek; Gai Liu; Wei Xu; Daisy W Leung; Christopher F Basler; Gaya K Amarasinghe
Journal:  Biochemistry       Date:  2013-11-14       Impact factor: 3.162

Review 9.  No exit: targeting the budding process to inhibit filovirus replication.

Authors:  Ronald N Harty
Journal:  Antiviral Res       Date:  2008-12-27       Impact factor: 5.970

10.  Clinical manifestations and case management of Ebola haemorrhagic fever caused by a newly identified virus strain, Bundibugyo, Uganda, 2007-2008.

Authors:  Paul Roddy; Natasha Howard; Maria D Van Kerkhove; Julius Lutwama; Joseph Wamala; Zabulon Yoti; Robert Colebunders; Pedro Pablo Palma; Esther Sterk; Benjamin Jeffs; Michel Van Herp; Matthias Borchert
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.